Skip to content

In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2

Lyubomir T. Vassilev, Binh Thanh Vu, Bradford J. Graves, Daisy M. Carvajal, Frank Podlaski, Zoran Filipovic, Norman Kong, U. Kammlott, Christine Lukacs, Christian Klein, Nader Fotouhi, Emily A. Liu

Science · 2004 · 4,728 citations

No retraction on record in OpenAlex.Check Crossref now

Cite this paper

Vassilev, L. T., Vu, B. T., Graves, B. J., Carvajal, D. M., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., Fotouhi, N., & Liu, E. A. (2004). In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science, 303(5659), 844–848. https://doi.org/10.1126/science.1092472

In text: (Vassilev et al., 2004)

Ask a question about this research

One question, free, no account. Anchorcite finds the papers, checks each against Crossref and links every sentence of the answer to the passage it comes from.

Abstract

MDM2 binds the p53 tumor suppressor protein with high affinity and negatively modulates its transcriptional activity and stability. Overexpression of MDM2, found in many human tumors, effectively impairs p53 function. Inhibition of MDM2-p53 interaction can stabilize p53 and may offer a novel strategy for cancer therapy. Here, we identify potent and selective small-molecule antagonists of MDM2 and confirm their mode of action through the crystal structures of complexes. These compounds bind MDM2 in the p53-binding pocket and activate the p53 pathway in cancer cells, leading to cell cycle arrest, apoptosis, and growth inhibition of human tumor xenografts in nude mice.

  1. Heat Shock Protein A12B Protects Vascular Endothelial Cells Against Sepsis-Induced Acute Lung Injury in Mice2017

Metadata from OpenAlex (CC0). Citations are generated from the published record.